Arbaclofen placarbil

Drug Profile

Arbaclofen placarbil

Alternative Names: AP; R-baclofen - XenoPort; XP-19986

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator XenoPort
  • Developer Indivior; XenoPort
  • Class Aminobutyric acids; Antispastics; Small molecules
  • Mechanism of Action GABA B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alcoholism
  • Discontinued Gastro-oesophageal reflux; Muscle spasticity; Spasm

Most Recent Events

  • 23 Jan 2017 Phase-I clinical trials in Alcoholism (In volunteers) in United Kingdom (PO) (NCT03058237)
  • 30 Mar 2016 Indivior completes a phase II trial for Alcoholism in USA (NCT02511886)
  • 01 Sep 2015 Phase-II clinical trials in Alcoholism in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top